Small-cell (Neuroendocrine) Cancer of the Cervix: The Latest Treatment Approaches
In this article
Small-cell neuroendocrine cancer of the cervix accounts for only approximately 1% of cervical cancers, yet is among the most challenging types because of its tendency to spread rapidly. Treatment is based on platinum and etoposide chemotherapy combined with surgery or radiotherapy. Drugs targeting DLL3 offer new hope. This article draws on MD Anderson NeCTuR data from the world's largest patient registry, as well as current clinical research.
- Rare and aggressive: Approximately 1% of cervical cancers; median age at diagnosis is 38. In the largest patient registry, 5-year overall survival was 71% in early-stage, 36% in locally advanced, and 12% in disseminated disease. Distant spread through the bloodstream is common even at an early stage.
- Standard treatment is multimodal: Radical surgery followed by chemotherapy in early-stage disease; concurrent chemoradiotherapy with cisplatin-etoposide and brachytherapy for large or locally advanced tumors. As in small-cell lung cancer, the platinum-etoposide regimen is the cornerstone.
- Immunotherapy alone has usually not worked: Two small studies specific to cervical neuroendocrine cancer found no responses to PD-1-targeting drugs. The most promising direction involves bispecific antibodies, antibody-drug conjugates, and CAR-T cells targeting DLL3, a protein present in most tumors; these remain in clinical research.
- When options become limited: Comprehensive tumor genetic testing (NGS), DLL3 testing, and HPV typing should be performed; pathology should be confirmed through a second opinion. Eligible patients can be referred to DLL3 and cellular therapy trials in the United States, Europe, and Asia.
Why Does This Matter?
The great majority of cervical cancers are squamous-cell carcinomas or adenocarcinomas, for which substantial advances have been made in screening, vaccination, and treatment. Small-cell neuroendocrine cancer has remained outside this progress. US cancer registry data show that this type accounted for only 1,0% of all cervical cancers during 2004-2021, although its proportion is rising by approximately 3,2% annually. Its occurrence in young women, rapid spread to distant organs even at an early stage, and the fact that large randomized trials have never been conducted leave patients and physicians facing difficult decisions.
Biologically, this cancer behaves similarly to small-cell lung cancer (SCLC) ; treatment has largely been adapted from SCLC experience. This resemblance raises the question of whether new drugs approved in SCLC could also offer hope to these patients. This article discusses standard treatment, new drugs, cellular therapies, therapeutic vaccines, and where patients can seek help around the world when treatment options become limited.
How is small-cell cancer of the cervix treated?
Small-cell neuroendocrine cancer of the cervix requires multimodal treatment combining chemotherapy with surgery or radiotherapy. Early-stage disease is treated with radical hysterectomy followed by platinum-etoposide chemotherapy; large or locally advanced tumors with concurrent cisplatin-etoposide chemoradiotherapy and brachytherapy. Platinum-etoposide is also the initial treatment for disseminated disease; topotecan, paclitaxel, and bevacizumab are an option.
What kind of disease is it?
| Feature | What is known |
|---|---|
| Frequency | Approximately 1% of cervical cancers (United States, 2004-2021: 539 among 54.987 patients); a single-center series from Türkiye found 9 neuroendocrine carcinomas among 453 patients (1,98%) |
| Age | Median age 38 (NeCTuR, 453 patients) |
| Stage at diagnosis (NeCTuR) | 29% early-stage, 50% locally advanced, 21% disseminated |
| Association with HPV | Approximately 85% of small-cell tumors are HPV-positive; mostly HPV18 (51%), with HPV16 alone in 10% |
| Pathology | Synaptophysin, chromogranin, CD56, and INSM1 staining support the diagnosis; INSM1 has 94% sensitivity and 98% specificity. TTF-1 may also be positive in tumors originating in the cervix, so differentiation from a lung metastasis requires clinical evaluation and imaging. |
| Genetic alterations | PIK3CA 18-20%, MYC 15%, TP53 15-17%, PTEN 14%, KRAS 7-11%; high tumor mutational burden in 2,1%, MSI-high in 2,7%. Genetically, it resembles other cervical cancers more than pulmonary SCLC. |
| DLL3 | Present in approximately 72-81% of tumors; strong (high) expression has been reported in 13% to 49% |
Accurate pathology is critical at diagnosis: small-cell, large-cell, and mixed types influence treatment. A second opinion from an experienced gynecological pathologist is recommended for this rare tumor. Although HPV-associated, its spread resembles small-cell lung cancer: rapid and through the bloodstream. Staging is recommended with whole-body PET-CT and brain MRI.
What can be expected at each stage?
Survival by stage
Percent. Colored bars: MD Anderson NeCTuR registry (453 patients); dark bars: US SEER cancer registry (2004-2021).
In the same SEER data, 5-year survival for other cervical cancer types was 82,5-91,3% at stage I and 18,2% at stage IV. Stage definitions differ between the two sources; they should not be compared directly.
Tumor size also matters in early-stage disease: in NeCTuR, 5-year progression-free survival was 68% for tumors 2 cm or smaller and 43% for tumors 2-4 cm. Recurrence is most often in distant organs (lung, liver, bone, brain). In one series, disease recurred in 66% of patients at a median of 8,4 months; recurrence within the radiotherapy field was rare. Systemic chemotherapy is therefore an indispensable part of treatment.
Standard treatment: a stage-based approach
No large randomized trial exists for this cancer. Recommendations are based on consensus reports from the Society of Gynecologic Oncology (SGO, 2011) and the Gynecologic Cancer InterGroup (GCIG, 2014), the US National Comprehensive Cancer Network (NCCN) guideline, and retrospective patient series. The shared principle is that surgery alone or radiotherapy alone is insufficient; platinum-etoposide chemotherapy must be part of treatment.
Figure 1 · Stage-based treatment of small-cell cervical cancer
Simplified diagram based on NCCN recommendations; the final decision is made by the multidisciplinary tumor board together with the patient.
What is the evidence based on?
| Study | Patients | Finding |
|---|---|---|
| Taiwanese Gynecologic Oncology Group (Wang, 2012) | 179 patients, retrospective | At stage IIB-IVB, 5-year cancer-specific survival was 75,0% for patients receiving chemoradiotherapy and at least 5 cycles of etoposide-platinum, versus 16,9% for others. The basis for the "at least 5 cycles" rule |
| Chinese multicenter study (Huang, 2014) | 72 patients, retrospective | 3-year overall survival was 64,8% with platinum-containing combination chemotherapy versus 25,2% with other treatments |
| NeCTuR (Salvo, 2023) | 453 patients, registry | In disseminated disease, platinum-etoposide (HR 0,33) and radiotherapy with curative intent (HR 0,32) were associated with better survival |
| US National Cancer Database (Wharton, 2020) | 542 patients | No difference between chemoradiotherapy and surgery + chemotherapy (median 44 versus 47 months); adding brachytherapy to chemoradiotherapy was associated with survival (35 versus 19 months) |
| Meta-analysis (Fan, 2025) | 5 studies, 650 patients, stage I-II | Favored surgery-first treatment (overall survival HR 0,53), but between-study heterogeneity and selection bias were high |
| MD Anderson (Stecklein, 2016) | 40 patients | In early-stage, node-negative patients, event-free survival was better with chemoradiotherapy than surgery |
Contribution of platinum-etoposide chemotherapy (retrospective data)
Percent. Colored bar: patients receiving intensive platinum-containing treatment; gray bar: other patients in the same series.
These comparisons are retrospective rather than randomized: patients able to receive more intensive treatment are generally younger and fitter (selection bias). Nevertheless, all series point in the same direction. EP: etoposide and platinum.
The question of surgery versus chemoradiotherapy remains unanswered: a meta-analysis favored surgery, an MD Anderson series favored chemoradiotherapy, and the US database found no difference. In practice, an experienced center should decide based on tumor size, lymph node status, and patient preference. Although prophylactic cranial irradiation is debated because of the risk of brain metastases, evidence is limited; in one series, the brain was never the first and only site of recurrence, and the authors considered this treatment's benefit low.
When the disease recurs or spreads
Platinum-etoposide remains the initial choice in disseminated or recurrent disease. In MD Anderson's retrospective study, patients received topotecan, paclitaxel, and bevacizumab (TPB): in 13 patients, median progression-free survival was 7,8 months versus 4,0 months with other regimens (HR 0,21); the response rate was approximately 46%. Overall survival did not differ (9,7 versus 9,4 months). There are no prospective data for second-line or subsequent treatment; drugs used for other cervical cancers (irinotecan, topotecan, taxanes) and drugs approved in SCLC are tried.
Does immunotherapy work in this cancer?
In other cervical cancers, immunotherapies such as pembrolizumab are part of standard treatment. However, most of these trials excluded the neuroendocrine type: KEYNOTE-826 included only squamous-cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. Evidence specific to the neuroendocrine type has been disappointing:
Response rates in recurrent disease: immunotherapy and chemotherapy
Objective response rate (percent). Colored bar: immunotherapy; gray bar: chemotherapy for comparison.
Median progression-free survival was 2,1-2,2 months in the pembrolizumab and cadonilimab studies. DART included tumors originating in different organs; cervical-specific results were not reported. Cadonilimab data come from a secondary source. Comparisons across trials are indirect: populations, prior treatments, and follow-up durations differ.
Nevertheless, the picture is not entirely negative. A 3-patient series showing durable responses and a case reporting a complete response to nivolumab plus ipilimumab in cervical neuroendocrine cancer have been published. This combination is also used for brain metastases in melanoma . In rare patients whose tumors are MSI-high or have a high mutational burden, immunotherapy may also be used under tumor-agnostic approvals. Immunotherapy decisions should therefore be based on biomarkers and preferably made within a clinical trial.
The newest direction: DLL3-targeted drugs
DLL3 is a protein normally found inside cells but present in abundance on the surface of neuroendocrine cancer cells. Its very low expression in healthy tissues makes it a good target. DLL3 is common in cervical neuroendocrine cancers: it was found in 81% of tumors in a molecular analysis of 62 patients and in 72,5% in a 2026 study of 91 patients. However, the rate of "high" expression varies between 13% and 49% across studies, and drug activity is seen largely in high-expressing tumors.
Figure 2 · How do DLL3-targeted drugs work?
Three different technologies use the same target.
| Drug | Type | Status | Evidence in extrapulmonary neuroendocrine cancer |
|---|---|---|---|
| Tarlatamab (Imdelltra) | DLL3 × CD3 bispecific | FDA approval in SCLC (accelerated May 2024, full November 2025); EU approval June 2026 | None. In SCLC, phase 3 DeLLphi-304 increased median overall survival from 8,3 to 13,6 months (HR 0,60). A phase 2 trial accepting neuroendocrine cancers of gynecological origin (TAURUS, Taiwan) is being planned |
| Obrixtamig (BI 764532) | DLL3 × CD3 bispecific | Investigational (Boehringer Ingelheim) | DAREON-1: in 60 patients, response was 40% in DLL3-high tumors versus 3,3% in low-expressing tumors; DAREON-7: 72% in 25 patients with first-line chemotherapy |
| Zocilurtatug pelitecan (ZL-1310) | DLL3 antibody-drug conjugate | Investigational (Zai Lab); FDA Fast Track designation (May 2026, extrapulmonary neuroendocrine cancer) | 38% response in 34 patients |
| MK-6070 (HPN328) | DLL3 × CD3 bispecific | Investigational (MSD) | Partial response in 2 of 2 patients with small-cell bladder cancer |
| LB2102, ML261 | DLL3 CAR-T | Phase 1 | LB2102: 28,6% response in 20 patients with tumors of pulmonary origin. ML261 (SPECTRAL-1, University of Washington) also accepts extrapulmonary neuroendocrine cancer |
Response rates with DLL3-targeted drugs
Objective response rate (percent). Colored bar: extrapulmonary neuroendocrine cancer; gray bar: tumors of pulmonary origin for comparison.
The red bar shows very limited activity in tumors with low DLL3 expression; DLL3 testing is therefore important. Cervical-specific results have not yet been reported. NEC: neuroendocrine carcinoma. Some of the response in DAREON-7 is attributable to chemotherapy. Comparisons across trials are indirect: populations, prior treatments, and follow-up durations differ.
The most important adverse effect of these drugs is cytokine release syndrome, caused by sudden activation of immune cells (fever, low blood pressure). It occurred in 70% with obrixtamig, but only 3,3% had grade 3 or higher events. We explain management of tarlatamab's adverse effects in this guide . For a patient with cervical neuroendocrine cancer, the practical implication is that DLL3 staining should be performed on the tumor; if expression is high, DLL3-targeted trials should be considered first. You can find an overview of new SCLC drugs in our article on new SCLC treatments in 2026 .
Other targets: B7-H3 and tissue factor
In the 2026 study of 91 patients, B7-H3 was present in 97,8% of cervical neuroendocrine cancers and tissue factor in 25,3%. B7-H3-targeting antibody-drug conjugates show promising results in SCLC (ifinatamab deruxtecan). Tissue factor-targeting tisotumab vedotin is approved for cervical cancer, but its approval trial excluded the neuroendocrine type. These targets remain investigational.
Lurbinectedin
Lurbinectedin (Zepzelca) received FDA approval in second-line SCLC (2020) and in first-line maintenance with atezolizumab (October 2025). However, in a basket study of neuroendocrine tumors, the response rate was only 6,5% and median progression-free survival 1,4 months; cervical-specific data are lacking. Caution is needed because tumor lysis syndrome causing death after a single dose was reported in a rapidly growing tumor.
Biomarker-based tumor-agnostic treatments
Some drugs are approved when a particular genetic alteration is present, regardless of the organ in which the tumor originated (tumor-agnostic treatments). These alterations are rare in cervical neuroendocrine cancer, but finding one opens an important option. Therefore, in advanced or recurrent disease, next-generation sequencing (NGS) is recommended.
| Biomarker | Frequency in this cancer | FDA-approved drug (tumor-agnostic) |
|---|---|---|
| MSI-high / MMR deficiency | %2,7 | Pembrolizumab (2017), dostarlimab (2021) |
| High tumor mutational burden | %2,1 | Pembrolizumab (2020) |
| HER2 (immunohistochemistry 3+) | ERBB2 alteration in 8,3% (at the gene level) | Trastuzumab deruxtecan (April 2024) |
| NTRK fusion | Very rare | Larotrectinib, entrectinib, repotrectinib |
| BRAF V600E | Very rare | Dabrafenib + trametinib (2022) |
| RET fusion | Very rare | Selpercatinib (2022) |
| PIK3CA, KRAS | 18,5% and 7,3% | No tumor-agnostic approval; clinical trial |
Cellular therapies and therapeutic vaccines
In HPV-associated cancers, the virus's E6 and E7 proteins are ideal targets for the immune system. Cellular therapies and therapeutic HPV vaccines are therefore being intensively investigated in cervical cancer. However, there is an important problem: most products target HPV16, whereas small-cell cervical cancer is mostly associated with HPV18. In addition, none of these studies reported patients with the neuroendocrine type; some explicitly excluded it.
| Treatment | Target and requirements | Results in cervical cancer (non-neuroendocrine types) | Status |
|---|---|---|---|
| TIL (tumor-infiltrating lymphocytes), lifileucel | T cells obtained from the patient's tumor; independent of HPV type | 44% response in 27 patients (3 complete responses) | FDA-approved in melanoma (Amtagvi); the company has no active cervical cancer program |
| TIL (US National Cancer Institute, 2015) | HPV-targeted T cells | 3 responses in 9 patients; 2 complete responses ongoing for 10 years | Academic |
| E7 TCR-T | HPV16 + HLA-A*02:01 tissue type | 6 responses in 12 patients in the initial study; 6 in 10 patients in phase 2 | Phase 2 (Rutgers, NCI) |
| VB10.16 + atezolizumab | HPV16 | 19,1% response | Second-line development discontinued (2024) |
| ISA101b + cemiplimab | HPV16 | 16,8% response; difference from cemiplimab alone unclear | No phase 3 trial |
| GX-188E + pembrolizumab | HPV16 or HPV18 | 35% response | Phase 2 completed (Korea) |
| BVAC-C + durvalumab | HPV16/18 | 38% response | Neuroendocrine and small-cell types excluded |
Figure 3 · When options become limited: which tests open which doors?
Each test determines eligibility for a particular treatment or clinical trial.
We explain the general principles of these treatments in our articles on immunotherapies and cancer vaccines, and CAR-T and bispecific antibodies . For work on a therapeutic HPV vaccine by a researcher from Türkiye, see this article .
Where in the world can patients seek help when treatment options become limited?
Experience with a cancer this rare is concentrated in a few centers. Much can be done before traveling abroad: most centers accept remote case review and international patient referrals. We suggest the following sequence:
- Prepare the records: Pathology blocks and report, all imaging (on CD), treatment summary, and recent blood test results, together with an English summary.
- Complete the tests: DLL3 staining, NGS, MSI/MMR, HER2, and HPV type. Without these results, eligibility for most clinical trials cannot be assessed.
- Request a remote second opinion: The international patient departments of the centers below can provide record-based assessment.
- Search clinical trials: ClinicalTrials.gov, the European Union clinical trials portal (euclinicaltrials.eu), and the World Health Organization trial registry system (trialsearch.who.int) can be searched using "neuroendocrine carcinoma cervix", "extrapulmonary neuroendocrine carcinoma", and "DLL3". Clinical trials and phase 1 trials are also covered in our articles explaining what patients need to know.
- Join the patient registry: MD Anderson's NeCTuR registry accepts patients at every stage; this registry is the source of much of the knowledge about this disease.
| Center / network | Why is it important? | Contact |
|---|---|---|
| MD Anderson Cancer Center (Houston, United States), Gynecologic Oncology | NeCTuR patient registry (since 2013, enrolling); source of most publications on this cancer; trials such as cadonilimab | necervix.com; nectur@mdanderson.org; international referral |
| Memorial Sloan Kettering (New York, United States) | Remote medical records review | international patients |
| US National Cancer Institute, Clinical Center (Bethesda) | Center where HPV-targeted TIL and TCR-T therapies were developed | patient referral office |
| Rutgers Cancer Institute (New Jersey, United States) | E7 TCR-T phase 2 (NCT05686226; HPV16 and HLA-A*02:01) | Contact details in the trial registry |
| Siteman Cancer Center, Washington University (St. Louis, United States) | DLL3 CAR-T (ML261, SPECTRAL-1), accepting extrapulmonary neuroendocrine cancer | siteman.washu.edu |
| Gustave Roussy (Paris, France) | One of Europe's largest cancer centers; early-phase trials | international patients |
| EURACAN, rare gynecological cancers domain | European rare cancer network of 20 centers in 18 countries; 260 patients reviewed in virtual tumor boards during 2017-2023 | ERN EURACAN |
| National Taiwan University Hospital (Taipei) | Tarlatamab phase 2 trial accepting neuroendocrine cancers of gynecological origin (TAURUS, NCT06816394) | Contact details in the trial registry |
Trials accepting extrapulmonary neuroendocrine cancer
| Trial | Drug | Who is eligible? |
|---|---|---|
| DAREON-5 (NCT05882058), Boehringer Ingelheim, phase 2 | Obrixtamig | Extrapulmonary neuroendocrine cancer after at least one platinum treatment; DLL3-high; centers in 12 countries |
| DAREON-7 (NCT06132113), phase 1 | Obrixtamig + platinum-etoposide | First-line treatment for DLL3-positive neuroendocrine cancer |
| TAURUS (NCT06816394), Taiwan, phase 2 | Tarlatamab | Extrapulmonary small-cell cancer, including gynecological origin (the registry indicates enrollment has not yet begun) |
| ZL-1310-002 (NCT06885281), Zai Lab, phase 1b/2 | Zocilurtatug pelitecan | Extrapulmonary neuroendocrine cancer cohorts |
| SPECTRAL-1 (NCT07488923), Washington University, phase 1 | ML261 (DLL3 CAR-T) | Including extrapulmonary neuroendocrine cancer |
| TAPUR (NCT02693535), ASCO, basket trial | Approved targeted drugs selected by genetic alteration | All solid tumors (United States) |
Trial recruitment status changes frequently; current registry information and eligibility criteria should be checked before applying.
Patient resources
- Foundation for Women's Cancer (SGO foundation): Patient information sheet on cervical neuroendocrine cancer (June 2024).
- Nichole Borchard Foundation (United States): Patient foundation focused on high-grade small-cell neuroendocrine cancers, including cervical cancer.
- NET Research Foundation: Neuroendocrine tumor specialist and support group locator.
- Mayo Clinic Connect: An active discussion group where patients with cervical neuroendocrine cancer share experiences.
Which commercial products are available?
No drug is specifically approved for small-cell cervical cancer. The drugs below are approved for other indications and are used in this cancer as part of standard regimens, according to biomarkers, or off-label.
| Brand name (active ingredient) | Company | Approved use | Role in this cancer |
|---|---|---|---|
| Etoposide, cisplatin, carboplatin (generic) | Various | Many cancers | Standard foundational treatment |
| Hycamtin (topotecan), Avastin and similar products (bevacizumab), paclitaxel | Various | Including cervical cancer | TPB regimen in recurrent/disseminated disease |
| Imdelltra (tarlatamab) | Amgen | SCLC after platinum (full FDA approval November 2025; EU June 2026) | Off-label; no data, trials ongoing |
| Zepzelca (lurbinectedin) | Jazz / PharmaMar | SCLC (second-line; maintenance with atezolizumab) | Off-label; low activity in neuroendocrine tumors |
| Keytruda (pembrolizumab) | MSD | Other types of cervical cancer; MSI-high and high-mutational-burden tumors | Only when a biomarker is present; found ineffective alone in the neuroendocrine type |
| Opdivo + Yervoy (nivolumab + ipilimumab) | BMS | Many cancers | Off-label; some durable responses in case series |
| Tivdak (tisotumab vedotin) | Genmab / Pfizer | Recurrent cervical cancer (FDA; EU March 2025) | Approval trial excluded the neuroendocrine type |
| Enhertu (trastuzumab deruxtecan) | AstraZeneca / Daiichi Sankyo | All solid tumors with HER2 immunohistochemistry 3+ (FDA) | Only if HER2 3+ |
| Amtagvi (lifileucel) | Iovance | Melanoma | Only investigational data in cervical cancer; no data for the neuroendocrine type |
- Data from Türkiye: In Akdeniz University's series, 9 of 453 cervical cancers (1,98%) were neuroendocrine carcinomas; mean overall survival was 26 months and 5-year survival 53,3%. We could not find a larger, multicenter Turkish series.
- Standard treatment: Platinum, etoposide, topotecan, paclitaxel, and bevacizumab are used in Türkiye; however, reimbursement conditions for bevacizumab and other drugs in this cancer should be checked separately.
- New drugs: See our relevant articles for tarlatamab's and lurbinectedin's authorization and reimbursement status in Türkiye; their use in this cancer will in all cases be off-label. We also explain off-label authorization and obtaining drugs from abroad , as well as litigation options if SGK does not reimburse them.
- Prevention: Most small-cell tumors are associated with HPV18; HPV vaccines cover HPV16 and HPV18. 20 years of HPV vaccination is the subject of our article discussing the vaccine's effects.
Frequently Asked Questions
- What is small-cell cancer of the cervix?
- A rare cancer accounting for approximately 1% of cervical cancers, with neuroendocrine cell characteristics, rapid growth, and the ability to spread to distant organs early. It is mostly associated with HPV18 and occurs in young women; median age at diagnosis is 38.
- What is standard treatment for small-cell cervical cancer?
- Treatment is multimodal. Early-stage disease is treated with radical surgery followed by platinum-etoposide chemotherapy; large or locally advanced tumors with concurrent cisplatin-etoposide chemoradiotherapy and brachytherapy. Platinum-etoposide is the initial treatment for disseminated disease.
- Does immunotherapy work in this cancer?
- PD-1-targeting immunotherapies alone produced no responses in small studies. However, durable responses to dual immunotherapy were reported in rare patients with MSI-high or high-mutational-burden tumors and in some case series. Decisions should be based on biomarkers.
- What can be done when treatment options are exhausted?
- Tumor testing should include DLL3, comprehensive genetic testing, MSI, and HER2. If DLL3 is high, DLL3-targeted bispecific antibody, antibody-drug conjugate, or CAR-T trials may be considered; if a biomarker is present, tumor-agnostic approved drugs become options. Remote second opinions can be obtained from experienced centers.
Glossary
- Neuroendocrine carcinoma
- A high-grade, rapidly growing cancer with features resembling nerve cells and hormone-secreting cells.
- Platinum-etoposide (EP)
- The foundational chemotherapy regimen for small-cell cancers, consisting of cisplatin or carboplatin plus etoposide.
- Chemoradiotherapy
- Radiotherapy delivered concurrently with chemotherapy.
- Brachytherapy
- Internal radiation treatment in which a radiation source is placed within or immediately next to the tumor.
- DLL3
- A protein abundant on neuroendocrine cancer cell surfaces but very scarce in healthy tissues; a target for new drugs.
- Bispecific T-cell engager
- An antibody that binds a tumor cell with one arm and a T cell with the other, directing the immune cell toward the tumor.
- TIL and TCR-T
- Therapies using T cells obtained from the patient's tumor or blood and expanded in the laboratory (TIL), or genetically modified to recognize a specific target (TCR-T).
- Tumor-agnostic approval
- Approval of a drug in the presence of a particular genetic alteration, regardless of the organ in which the tumor originated.
DROZDOGAN Academy Commentary
Evidence is scarce in rare cancers, but this does not mean there is no knowledge. The right center, the right tests, and the right trial can change the outcome in this disease.
⚡ Why it matters
Correctly planning initial treatment is critical in this cancer, which affects young women and spreads rapidly. Adding platinum-etoposide chemotherapy is the factor most strongly associated with survival in retrospective data.
✅ Strengths
MD Anderson's 453-patient registry and international consensus reports established a consistent standard. The presence of DLL3 in most tumors provides a rational bridge to drugs with proven activity in SCLC.
⚠️ Limitations
All evidence comes from retrospective data or small groups, with substantial selection bias. DLL3-targeted drugs have no cervical cancer-specific results. Cellular therapies and vaccines mostly target HPV16 and have not been tested in the neuroendocrine type.
🩺 In practice
At diagnosis: a second pathology opinion, PET-CT, and brain MRI. For treatment: a multimodal plan including platinum-etoposide. In recurrent or disseminated disease: DLL3, NGS, MSI, and HER2 testing, with early evaluation for clinical trials.
❓ Open questions
Surgery or chemoradiotherapy in early-stage disease? Is prophylactic cranial irradiation necessary? Will DLL3-targeted drugs be as effective in this cancer as in SCLC? Can cellular therapies targeting HPV18 be developed?
Conclusion: Standard treatment for small-cell cervical cancer is a multimodal approach including platinum-etoposide. When options become limited, biomarker-guided DLL3-targeted clinical trials offer the most promising pathway. Early contact with experienced centers is valuable in this rare disease.
- This article was prepared in October 2026.
- Treatment recommendations rely on a secondary source reporting the 2024 NCCN guideline; whether this section changed in the 2026 version could not be verified. ESGO guideline statements regarding the neuroendocrine type could not be accessed.
- All evidence comes from retrospective series, patient registries, and small phase 1-2 trials. Comparisons across different studies in the charts are indirect.
- Cadonilimab trial results and DLL3 rates in a 2026 pathology study were taken from secondary summaries. Clinical trial recruitment status was compiled from mirror sites of ClinicalTrials.gov and may have changed.
- Cellular therapy and vaccine results concern non-neuroendocrine cervical cancers.
- The drugs' authorization and reimbursement status in Türkiye could not be separately verified for this article.
- The lists of centers and trials are illustrative rather than exhaustive; they are not intended to endorse or advertise any institution.
- The diagrams are derived from verified statements in the text; they contain no new data. The Academy commentary is our own.
Was this article helpful?
Your feedback helps us improve our content.
